SynthesisInternational journal of pharmaceutics2025
Repurposing neurological drugs for brain cancer therapeutics: A systematic approach to identify charged molecules for affinity-based local drug delivery systems.
Synthesis in International journal of pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- QRICH1 Suppresses Glioma Progression by Inducing ER Stress and Activating the PERK-ATF4-CHOP Pathway.Cancer medicine · 2026Article
- Oligodendrocyte: Development, Plasticity, Biological Functions, Diseases, and Therapeutic Targets.MedComm · 2026Review
- Effect of anticancer activity of aripiprazole main metabolite OPC-14857 on malignant glioblastoma.PloS one · 2026Article
- A network-driven computational framework for identifying FDA-approved drug repurposing across heterogeneous brain cancers.Frontiers in molecular biosciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment of glioblastoma (GBM) presents significant challenges due to its high degree of heterogeneity and poor prognosis. Recurrence of the malignancy is frequent even after the standard treatment, including surgery, radiotherapy, and chemotherapy with temozolomide. Drug repurposing offers a cost-effective strategy to identify new treatments, while affinity-based local delivery systems could provide controlled release of therapeutics within the tumor resection cavity. The aims of this study are two-fold. Firstly, to categorize currently available neurological therapeutics according to their charge and suitability for use with affinity-based drug delivery systems. Secondly, to systematically search and evaluate the evidence for anticancer and/or anti-glioblastoma activity for potentially being repurposed/repositioned. The 'neurology/psychiatry' category of the Broad Institute Drug Repurposing Hub (468 compounds) was screened for chemical suitability and anticancer efficacy. Charge, lipophilicity, solubility at pH 7.4 were calculated using Chemicalize. A systematic search for the anticancer efficacy of the charged compounds was carried out via the following databases: PubMed, Scopus, Sci-Finder, Ovid via Medline, Cochrane and ClinicalTrial.gov. Among the 468 compounds, 283 were identified as charged at physiological pH. Notably, 146 charged candidates were found to have anticancer activity, of which 91 showed promising activity against at least one type of brain neoplasm. A few compounds, such as chlorpromazine, valproic acid and sertraline were investigated in clinical settings, while most were assessed through in vitro viability studies. The data complied herein should serve as a repository and starting point for future research on repurposing neurological drugs with anticancer properties via electrostatic affinity-based drug delivery systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.